Survival Improvement in Korean Breast Cancer Patients Due to Increases in Early-Stage Cancers and Hormone Receptor Positive/HER2 Negative Subtypes: A Nationwide Registry-Based Study-Reference-Cited by-同舟云学术

Survival Improvement in Korean Breast Cancer Patients Due to Increases in Early-Stage Cancers and Hormone Receptor Positive/HER2 Negative Subtypes: A Nationwide Registry-Based Study

Published:2015 Issue:1 Volume:18 Page:8
ISSN:1738-6756
Container-title:Journal of Breast Cancer
language:en
Short-container-title:J Breast Cancer

Author:

You Jee Man¹,Kim Yun Gyoung²,Moon Hyeong-Gon²,Nam Seok Jin³,Lee Jong Won⁴,Lim Woosung⁵,Lee Mi-Ri⁶,Noh Dong-Young²,Han Wonshik²

Affiliation:

1. Department of Surgery, Sun Medical Center, Daejeon, Korea.

2. Department of Surgery, Seoul National University Hospital, Seoul, Korea.

3. Department of Surgery, Samsung Medical Center, Seoul, Korea.

4. Department of Surgery, Asan Medical Center, Seoul, Korea.

5. Department of Surgery, Ewha Womans University Mokdong Hospital, Seoul, Korea.

6. Department of Surgery, Dong-A University College of Medicine, Busan, Korea.

Funder

Ministry of Health and Welfare

National Research Foundation of Korea

Publisher

Korean Breast Cancer Society

Subject

Cancer Research,Oncology

Link

https://synapse.koreamed.org/pdf/10.4048/jbc.2015.18.1.8

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-utility analysis of eribulin versus capecitabine in HER-2 negative advanced or metastatic breast cancer in China;2022-12-02

2. Improvement of survival in Korean breast cancer patients over a 14-year period: A large-scale single-center study;PLOS ONE;2022-03-16

3. The economic impact of disease progression and death in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients: using Korean nationwide health insurance claims data;Current Medical Research and Opinion;2020-10-05

4. Insights Into Breast Cancer in the East vs the West;JAMA Oncology;2019-10-01

5. Event-free survival following early endometrial events in breast cancer patients treated with anti-hormonal therapy;Medicine;2019-01